It was a pleasure to catch up with our Editorial Board member Prof. Farhad Hafezi (ELZA Institute, Zurich, Switzerland), the winner of the ESCRS 2020 Refractive Award! Here he discusses the PACK-CXL multicentre trial, and the benefits of this treatment.
Questions
- What are the major challenges in the treatment of infectious keratitis? (00:15)
- Could you give us a brief overview of the photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL) treatment and its advantages compared to standard protocols? (01:57)
- Could you tell us about the PACK-CXL multicentre trial, including the major findings? (03:51)
Speaker Disclosures: Prof. Farhad Hafezi holds patents and applications fo corneal apparatus used for CXL, chromophore for CXL application; and is a shareholder and investor for EMAGine AG.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ESCRS 2020.
